- Pressemitteilung BoxID 130201
Roche NimbleGen Arrays Help Unveil the Secrets of Insidious Potato Blight
Yearly potato production (300 Mt) substantially contributes to worldwide food security, surpassed only by wheat (630 Mt) and rice (608 Mt)(2). While it is important to identify the problem genes responsible for infection, it is equally important to identify the genes that develop resistance.
Brian J. Haas, a primary contributor from the Broad Institute of MIT and Harvard, noted that "NimbleGen services generated the data that made it possible for us to identify key genes in pathogenesis, as described in our recent Nature publication on the potato blight genome. In particular we identified a large number of so-called effector genes that are critical to pathogenesis that had been previously unknown and are extremely challenging to predict because of their small size and unusual structure."
Senior author Chad Nusbaum, co-director of the Broad Institute's Genome Sequencing and Analysis Program, added that "NimbleGen services generated data that made it possible for us to identify these genes in a timely and cost-competitive manner."
The authors capitalized on Roche NimbleGen's flexible array design capability to use the data from the newly sequenced genome to build a custom gene expression microarray, which helped measure gene level changes between the vegetative stage and infection stage. Nearly 3% of approximately 18,000 genes analyzed on the NimbleGen Gene Expression microarray are induced at least twofold during infection. Some of the induced genes belong to gene families with functions previously known to be involved in infection, such as RXLR genes, which may maintain virulence by suppressing host cell death. Understanding the P. infestans genes responsible for potato blight, and having unraveled its genetic code, will lead to methods for controlling the infection to improve food production and reduce the impact on worldwide crop losses.
(1) BJ Haas, S Kamoun, et al., Nature 2009 September 17; 241: 393-398; doi: 10.1038/nature08358
(2) AJ Haverkort, PC Struik, et al., Potato Res 2009 August 8; 52:249-264; doi: 10.1007/s11540-009-9136-3
For more information about Roche NimbleGen, please visit www.nimblegen.com
Roche Diagnostics GmbH
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Diese Pressemitteilungen könnten Sie auch interessieren
Anfang Mai fand die mittlerweile fünfte Hanauer Gesundheitsmesse statt, die auch in diesem Jahr wieder mehrere Tausend interessierte Besucher...
Medexo und DAK-Gesundheit kooperieren bei medizinischen Zweitmeinungen vor orthopädischen Operationen
Die Medexo GmbH, ein eHealth-Unternehmen und Zweitmeinungsexperte aus Berlin, und die DAK-Gesundheit kooperieren bei einem Angebot für medizinische...
Extrakorporale Stoßwellentherapie beim Fersenschmerz: besser als Placebo, Ultraschall und Iontophorese
Eine Reizung und Entzündung der sogenannten plantaren, also in der Fußsohle gelegenen Sehnenplatte am Fersenbein kann zu Gewebsveränderungen...